E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
We are investigating the effects of Simvastatin 80mg on neutrophil function (using in vitro studies of neutrophil function), in healthy elderly subjects as there is evidence to suggest that Simvastatin may improve neutrophil responses to inflammation in this population. Clinical and experimental data have suggested that response to infection is improved in patients receiving statins. Our own preliminary in vitro data suggest that this may be due to enhance neutrophil migration. |
|
E.1.1.1 | Medical condition in easily understood language |
Healthy older subjects. The usual indication for Simvastatin is to treat raised cholesterol levels in people at risk of heart disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Hypothesis. The age-related loss of neutrophil function contributes to delayed resolution of infection and inflammation. These changes in neutrophil function with advanced age are a result of alterations in signal transduction pathways due to altered membrane cholesterol levels and can be corrected using simvastatin. In vitro studies have confirmed that neutrophils isolated from elderly subjects respond differently to those from young donors in terms of migration, phagocytosis and superoxide production when pre-treated with physiological concentrations of Simvastatin. Question: Is this clinically relevant in vivo? Does a course of treatment with simvastatin improve migratory dynamics, phagocytosis and superoxide generation of neutrophils isolated from the peripheral blood of older subjects and is this associated with altered membrane cholesterol levels? |
|
E.2.2 | Secondary objectives of the trial |
There are no secondary questions. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria 1. Age > 60 years 2. Competent to provide informed consent and participate 3. MRC Dyspnoea scale < 2 4. Normal lung function (FEV1 > 80% predicted, FVC > 80% predicted) 5. Normal peripheral oxygenation (as assessed by pulse oximetry, with oxygen saturations above 92%) 6. Free from medications known to alter immune cell function (as outlined in protocol) 7. No clinical evidence of acute infection or chronic illness. 8. Normal liver and kidney function as assessed by peripheral blood liver function tests, urea and creatinine and urinary dipstick. |
|
E.4 | Principal exclusion criteria |
Exclusion criteria 1. Unable to provide informed written consent 2. History of significant chronic illness including Diabetes, COPD, Asthma, TB, Bronchiectasis, Malignancy, Auto immune disease, Cardiovascular disease. 3. Clinical evidence of acute viral or bacterial infection 4. Any regular medical therapies that may alter immune function 5. Declines to provide permission for GP to be informed 6. Any contraindications for statin therapy (hypersensitivity or abnormal renal or liver function tests) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Assessment of adhesion, chemokinesis and chemotaxis by neutrophils Neutrophil adhesion and migration will be assessed in a microscopy slide based system using established methodology (35). Chemoattractants used will be those that act via CXC receptors (CXCL8 and GROα), those that act through other receptors (e.g., fMLP). 2. Cell surface receptors. Isolated neutrophils from both media will also be used to measure surface expression of receptors known to be important in chemotaxis, including CXCR1, CXCR2, CD11, CD18, CD44, CD47 and CD55, using FACS analysis, to assess differences in migratory receptor and opsonisation receptor expression. 3. Assessment of bacterial killing The phagocytic function and superoxide production of neutrophils will be examined using standard assays. Respiratory burst in response to fMLP will be determined in isolated neutrophils by measuring the generation of superoxide in a lucigenin-based assay. Phagocytosis of E Coli by neutrophils will be measured using a commercially available kit (Phagotest, Orpegen, Germany). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Cell studies will be performed after completion of the first arm of the crossover study and following completion of the study. |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be the last visit of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 24 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 25 |